Model Medicines Selected to Present at the 2022 BIO International Convention, Following Recent Submission of a Pre-IND Briefing Document and Meeting Request to the FDA
Dr. Daniel Haders, founder and CEO of Model Medicines will be presenting at this year’s Bio International Conference in San Diego, speaking to the recent data showing MDL-001 has demonstrated potential best-in-class combination of: viral load reduction, symptom reduction, activity against sars-cov-2 variants and pan antiviral activity.
The Model Medicines’ technology platform and drug hunting expertise are now responsible for one of the world’s first AI-discovered drugs to achieve this stage of development.
This places the company in an exclusive group of AI-drug discovery companies known to have discovered a small molecule therapeutic using AI and brought it to this stage of development.
Model Medicines recently completed a submission of a Pre-IND Briefing Document and Meeting Request to the FDA for MDL-001.
Model Medicines is participating in a manuscript in collaboration with research partners, Arnab Chatterjee, PhD, at California Institute for Biomedical Research (Calibr), Scripps Research, as well as Adolfo Garcia-Sastre, PhD, and Kris White, PhD, at the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine.
LA JOLLA, CA., June 1, 2022 -- Model Medicines, the pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), today announced that the company will present at in the 2022 Bio International Conference. This announcement follows recent positive data the company recently released surrounding its Oral Anti-COVID-19 Drug Candidate MDL-001 and their submission of a Pre-IND Briefing Document and Meeting Request to the FDA for MDL-001. This places the company in an exclusive group of AI-drug discovery companies known to have discovered a small molecule therapeutic using AI and brought it to this stage of development. MDL-001’s antiviral activity was discovered by Model Medicines’ CHEMprint™ AI-drug discovery platform and developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai. The drug is being developed as a therapeutic with broad antiviral activity with a lead indication in SARS-CoV-2/COVID-19.
Dr. Daniel Haders, founder and CEO of Model Medicines stated, “Our acceptance to present at BIO 2022 is meaningful and represents a unique and important opportunity not just for Model Medicines, but AI-drug discovery. At our core, we’re a pharmaceutical company, leveraging technology to create drugs faster, better, cheaper, and in a more repeatable fashion. Since inception, we have been focused on discovering drugs, not merely creating thousands of hits that never reach the clinic or pharmacy. We brought MDL-001 from concept to Pre-IND submission, in less than 2 years with less than $4M in capital.In total, we’ve discovered novel biological activity for 70+ de-risked assets, all based on unique scaffolds for 10+ targets, for multiple indications, validated with multiple, world-renowned research institutes. We’re delivering on the promise of faster, better, cheaper drugs.”
Data presented in Dr. Haders’ presentation will be the subject of a manuscript being completed in collaboration with research partners, Arnab Chatterjee, PhD, at California Institute for Biomedical Research (Calibr), Scripps Research, as well as Adolfo Garcia-Sastre, PhD, and Kris White, PhD, at the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine.
Dr. Daniel Haders, founder and CEO of Model Medicines, is scheduled to present at Bio International 2022 on Monday, June 13th at 4:30PM PST in Theater 4.
ABOUT BIO INTERNATIONAL
BIO 2022 is the world’s largest and most influential event for the pharmaceutical and biotechnology industry. This year’s meeting will be held in San Diego, California from June 13 to 16, 2022, as a fully in-person meeting for the first time in three years.
ABOUT THE MDL-001 DEVELOPMENT PROGRAM
MDL-001 is an oral, direct-acting antiviral agent that is currently undergoing IND (Investigational New Drug) enabling preclinical evaluation as a treatment for patients with COVID-19 in collaboration with partners including Calibr Scripps Research, the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine and the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Disease (NIAID) and National Institutes of Health (NIH) as part of the Antiviral Program for Pandemics (APP). Model Medicine has submitted a Pre-IND Briefing Document and Meeting Request data package to the FDA (Food and Drug Administration) for MDL-001. This request for a pre-IND Meeting has been granted.
ABOUT MODEL MEDICINES
Model Medicines is an artificial intelligence and machine learning Drug Discovery company that reduces the time to bring a drug to market by 10+ years and the cost to bring a drug to market by $1B+. Model Medicines is transforming drug discovery by leveraging the historical compendium of drug development data, a drug and disease agnostic discovery platform, and unbiased AI to create Phase II/III ready drug candidates in months rather than years. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA. www.modelmedicines.com
